BIO.B Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Rad Laboratories Inc. is not a strong buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The lack of strong positive catalysts, weak financial performance, and mixed analyst sentiment make it prudent to hold rather than buy at this time.
The MACD is positive and contracting, indicating a potential weakening of upward momentum. RSI is neutral at 51.343, showing no clear overbought or oversold conditions. Moving averages are converging, suggesting indecision in the market. Key resistance levels are at 285.43 and 290.546, while support levels are at 268.866 and 263.75.
Hedge funds are significantly increasing their positions, with a 333305.80% rise in buying activity over the last quarter. The company's portfolio assessment could present opportunities, as noted by analysts.
The company's Q4 financials show a significant decline in net income (-200.59% YoY) and EPS (-204.22% YoY), alongside a drop in gross margin (-2.89% YoY). Analysts have lowered price targets, citing messy margins and weak 2026 guidance. No recent news or congress trading data provides additional support for a buy.
In 2025/Q4, revenue increased by 3.85% YoY to $693.2M, but net income dropped by -200.59% YoY to $720M. EPS fell by -204.22% YoY to 26.65, and gross margin declined to 49.74%, down -2.89% YoY. These metrics indicate weak profitability and operational challenges.
Analysts have mixed views. Wells Fargo lowered the price target to $320 from $340, maintaining an Equal Weight rating, citing weak guidance and a Q4 miss. UBS lowered the price target to $335 from $350 but maintained a Buy rating, noting bright spots despite messy margins.
